Sequenom Inc. (SQNM): Today's Featured Drugs Winner

Sequenom ( SQNM) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 1.8%. By the end of trading, Sequenom rose 12 cents (2.3%) to $5.40 on heavy volume. Throughout the day, 14.2 million shares of Sequenom exchanged hands as compared to its average daily volume of 3.2 million shares. The stock ranged in a price between $5.05-$5.83 after having opened the day at $5.10 as compared to the previous trading day's close of $5.28. Other companies within the Drugs industry that increased today were: Cormedix ( CRMD), up 16.7%, Opexa Therapeutics ( OPXA), up 15.1%, Aoxing Pharmaceutical Company ( AXN), up 13.9%, and Transition Therapeutics ( TTHI), up 10%.

Sequenom, Inc. provides products, services, diagnostic testing, applications, and genetic analysis products that translate the results of genomic science into solutions for biomedical research, translational research, molecular medicine applications, and agricultural and livestock research. Sequenom has a market cap of $614.5 million and is part of the health care sector. Shares are up 18.7% year to date as of the close of trading on Thursday. Currently there are eight analysts that rate Sequenom a buy, no analysts rate it a sell, and four rate it a hold.

TheStreet Ratings rates Sequenom as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, weak operating cash flow, generally disappointing historical performance in the stock itself and unimpressive growth in net income.

On the negative front, Synergy Pharmaceuticals ( SGYP), down 20.9%, Alexza Pharmaceuticals ( ALXA), down 19.7%, Anika Therapeutics ( ANIK), down 17%, and Cadence Pharmaceuticals ( CADX), down 16.7%, were all losers within the drugs industry with Johnson & Johnson ( JNJ) being today's drugs industry loser.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing